Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04HWF
|
|||
| Former ID |
DNC010726
|
|||
| Drug Name |
Talmapimod
|
|||
| Synonyms |
Talmapimod; SCIO-469; 309913-83-5; Scios 469; UNII-B1E00KQ6NT; SCIO 469; B1E00KQ6NT; CHEMBL514201; SCIO 469 hydrochloride; CHEBI:90683; Talmapimod hydrochloride; 2-(6-Chloro-5-{[(2r,5s)-4-(4-Fluorobenzyl)-2,5-Dimethylpiperazin-1-Yl]carbonyl}-1-Methyl-1h-Indol-3-Yl)-N,N-Dimethyl-2-Oxoacetamide; 2-[6-chloro-5-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine-1-carbonyl]-1-methylindol-3-yl]-N,N-dimethyl-2-oxoacetamide; 750646-72-1; Talmapimod [USAN]; Talmapimod [USAN:INN]
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H30ClFN4O3
|
|||
| Canonical SMILES |
CC1CN(C(CN1C(=O)C2=C(C=C3C(=C2)C(=CN3C)C(=O)C(=O)N(C)C)Cl)C)CC4=CC=C(C=C4)F
|
|||
| InChI |
1S/C27H30ClFN4O3/c1-16-13-33(17(2)12-32(16)14-18-6-8-19(29)9-7-18)26(35)21-10-20-22(25(34)27(36)30(3)4)15-31(5)24(20)11-23(21)28/h6-11,15-17H,12-14H2,1-5H3/t16-,17+/m0/s1
|
|||
| InChIKey |
ZMELOYOKMZBMRB-DLBZAZTESA-N
|
|||
| CAS Number |
CAS 309913-83-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14836093, 24161762, 45293334, 53789617, 77593007, 89449456, 96026066, 103631444, 104114030, 126680718, 134338888, 134347931, 135261043, 135261937, 136023574, 137236361, 137275984, 143330320, 164233893, 164765203, 165245605, 180411469, 184816785, 198945302, 223366148, 223667449, 223704858, 230673875, 243095993, 252160350
|
|||
| ChEBI ID |
CHEBI:90683
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7817). | |||
| REF 2 | Mitogen-activated protein kinases in innate immunity.Nat Rev Immunol.2013 Sep;13(9):679-92. | |||
| REF 3 | p38 MAP Kinase Inhibition Reduces Propionibacterium acnes-Induced Inflammation in Vitro. Dermatol Ther (Heidelb). 2015 Mar;5(1):53-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.